Bioactive Metabolites from the Deep-Sea-Derived Fungus Diaporthe longicolla FS429

Zhaoming Liu, Yuchan Chen, Saini Li, Qinglin Wang, Caiyun Hu, Hongxin Liu, Weimin ZhangMarine 2020 · DOI

TL;DR

Researchers have isolated and characterized nine compounds, including six novel natural products, from the deep-sea fungus Diaporthe longicolla. Among these, one compound, longichalasin B, showed promising antiproliferative activity against the SF-268 cancer cell line, and two compounds demonstrated weak inhibitory effects against a key enzyme in Mycobacterium tuberculosis.

What Problem Does This Paper Address?

Deep-sea environments, characterized by extreme conditions like high pressure, low temperature, and limited nutrients, are increasingly recognized as rich sources of novel bioactive compounds produced by microorganisms. Fungi, in particular, are known to synthesize a diverse array of secondary metabolites with potential pharmaceutical applications. However, exploring these unique ecosystems for new drug leads is challenging due to the difficulty of sample collection and the complex chemical structures often produced by these organisms. This paper addresses the need to discover and characterize new bioactive molecules from these underexplored environments, specifically focusing on a fungus isolated from the deep sea.

Methods

The study employed a multi-faceted approach combining advanced spectroscopic techniques and biological assays:

  • Chemical Isolation and Structure Elucidation: The methanol extract of the Diaporthe longicolla FS429 fungus was subjected to extensive chromatographic separation (silica gel column chromatography, Sephadex LH-20, and preparative HPLC) to isolate individual compounds.
  • Spectroscopic Analysis: High-resolution electrospray ionization mass spectrometry (HRESIMS) was used to determine the molecular formulas of the isolated compounds. Nuclear Magnetic Resonance (NMR) spectroscopy (1D: ¹H, ¹³C, and 2D: COSY, HMBC, HSQC) was extensively used to determine the planar structures of the compounds.
  • Absolute Configuration Determination: For novel compounds, the absolute configurations were established by comparing experimental Electronic Circular Dichroism (ECD) spectra with theoretically calculated ECD spectra using Density Functional Theory (DFT) at the B3LYP/6-311+G(d,p) level. For one compound (7), its structure was definitively confirmed through X-ray diffraction analysis.
  • Bioassays: The isolated compounds were evaluated for their in vitro cytotoxicity against four human cancer cell lines (SF-268, MCF-7, HepG-2, and A549) using a standard SRB assay. Additionally, their inhibitory activity against Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) was assessed.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Deep-Sea Fungi as a Treasure Trove: This study reinforces the notion that deep-sea-derived fungi are a significant source of structurally diverse and potentially bioactive secondary metabolites. The isolation of six new compounds from a single fungal strain highlights this potential.
  • Structural Novelty: The paper describes novel diterpenoids (longidiacids A and B), polyketides, and cytochalasin analogues, showcasing the unique biosynthetic capabilities of this deep-sea fungus.
  • ECD Spectroscopy for Absolute Configuration: The successful application of ECD spectroscopy, coupled with quantum chemical calculations, for determining the absolute configuration of complex natural products is a key methodological insight. This is crucial for understanding structure-activity relationships.
  • X-ray Crystallography as the Gold Standard: The confirmation of compound 7's structure via X-ray diffraction underscores its importance in definitively assigning the stereochemistry of complex molecules when possible.
  • Dual Bioactivity: The identification of antiproliferative activity against cancer cells and inhibitory effects against a key bacterial enzyme demonstrates the potential for these compounds to serve as leads for both anticancer and anti-infective drug development.

Key Results

  • Six New Compounds: Two novel diterpenoids (longidiacids A and B), two new polyketides (3 and 4), and two new cytochalasin analogues (longichalasins A and B, 6 and 8) were isolated and characterized.
  • Three Known Compounds: Compounds 5, 7, and 9 were also identified.
  • Antiproliferative Activity: Longichalasin B (8) exhibited significant antiproliferative activity against the SF-268 cancer cell line with an IC50 value of 16.44 µM. Compounds 4, 6, 7, and 9 showed marginal activity at a higher concentration (100 µM).
  • MptpB Inhibition: Compounds 1 and 8 showed weak inhibitory activity against Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB), inhibiting 35.4% and 53.5% of enzyme activity, respectively, at 50 µM.

Limitations and Future Work

  • Limited Potency: While novel compounds were discovered, the observed bioactivities, particularly the MptpB inhibition, were described as "weak." Further optimization or structural modifications might be necessary to enhance potency.
  • Mechanism of Action: The paper focuses on the isolation and structural elucidation of the compounds and their general bioactivities. Further studies would be needed to elucidate the precise mechanisms of action for the observed antiproliferative and inhibitory effects.
  • Broader Screening: The bioactivity screening was limited to four cancer cell lines and one bacterial enzyme. Expanding the screening panel to include a wider range of cancer types, infectious agents, or other biological targets could reveal additional therapeutic potential.
  • Synthetic Accessibility: For compounds showing promising activity, exploring their synthetic accessibility would be a logical next step for large-scale production and further derivatization.

Summary updated

Abstract

The chemical investigation of a methanol extract of the deep-sea-derived fungus Diaporthe longicolla FS429 led to the isolation of two novel diterpenoids longidiacids A and B (1 and 2), two new polyketides (3 and 4), two new cytochalasin analogues longichalasins A and B (6 and 8) and three known analogues 5, 7, 9. Their structures were elucidated through comprehensive spectroscopic analysis, while the absolute configurations were established by the comparison of the experimental and quantum chemical calculated ECD spectra. The structure of compound 7 was confirmed through X-ray diffraction for the first time. In the bioassays compound 8 exhibited antiproliferative effects against SF-268, with an IC50 value of 16.44 μM. Moreover, compounds 1 and 8 were detected to inhibit 35.4% and 53.5% of enzyme activity of Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) at a concentration of 50 μM.
BibTeX
@inproceedings{liu2020bioactive,
  author = {Zhaoming Liu and Yuchan Chen and Saini Li and Qinglin Wang and Caiyun Hu and Hongxin Liu and Weimin Zhang},
  title = {{Bioactive Metabolites from the Deep-Sea-Derived Fungus Diaporthe longicolla FS429}},
  booktitle = {Marine},
  year = {2020},
  doi = {10.3390/md18080381},
}
Figure